company background image
ALBO

Albireo PharmaNasdaqCM:ALBO Stock Report

Market Cap

US$604.1m

7D

1.9%

1Y

-5.8%

Updated

26 Sep, 2021

Data

Company Financials +
ALBO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ALBO Overview

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.

Price History & Performance

Summary of all time highs, changes and price drops for Albireo Pharma
Historical stock prices
Current Share PriceUS$31.37
52 Week HighUS$27.23
52 Week LowUS$43.41
Beta1.51
1 Month Change5.20%
3 Month Change-12.08%
1 Year Change-5.82%
3 Year Change-4.82%
5 Year Changen/a
Change since IPO114.86%

Recent News & Updates

Shareholder Returns

ALBOUS BiotechsUS Market
7D1.9%-2.3%0.1%
1Y-5.8%26.0%35.3%

Return vs Industry: ALBO underperformed the US Biotechs industry which returned 26% over the past year.

Return vs Market: ALBO underperformed the US Market which returned 35.3% over the past year.

Price Volatility

Is ALBO's price volatile compared to industry and market?
ALBO volatility
ALBO Beta1.51
Industry Beta1.03
Market Beta1

Stable Share Price: ALBO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ALBO's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a90Ron Cooperhttps://www.albireopharma.com

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis.

Albireo Pharma Fundamentals Summary

How do Albireo Pharma's earnings and revenue compare to its market cap?
ALBO fundamental statistics
Market CapUS$604.06m
Earnings (TTM)-US$135.70m
Revenue (TTM)US$9.24m

65.4x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALBO income statement (TTM)
RevenueUS$9.24m
Cost of RevenueUS$0
Gross ProfitUS$9.24m
ExpensesUS$144.94m
Earnings-US$135.70m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-7.05
Gross Margin100.00%
Net Profit Margin-1,468.41%
Debt/Equity Ratio8.7%

How did ALBO perform over the long term?

See historical performance and comparison

Valuation

Is Albireo Pharma undervalued compared to its fair value and its price relative to the market?

5.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALBO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALBO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALBO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALBO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALBO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALBO is overvalued based on its PB Ratio (5.3x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is Albireo Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

63.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALBO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALBO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALBO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALBO's revenue (58.4% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: ALBO's revenue (58.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Albireo Pharma performed over the past 5 years?

-44.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALBO is currently unprofitable.

Growing Profit Margin: ALBO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 44% per year.

Accelerating Growth: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ALBO has a negative Return on Equity (-119.55%), as it is currently unprofitable.


Financial Health

How is Albireo Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ALBO's short term assets ($195.3M) exceed its short term liabilities ($27.0M).

Long Term Liabilities: ALBO's short term assets ($195.3M) exceed its long term liabilities ($79.0M).


Debt to Equity History and Analysis

Debt Level: ALBO's debt to equity ratio (8.7%) is considered satisfactory.

Reducing Debt: ALBO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALBO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALBO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 48% each year.


Dividend

What is Albireo Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALBO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALBO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALBO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALBO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALBO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Ron Cooper (58 yo)

6.17yrs

Tenure

US$3,460,444

Compensation

Mr. Ronald H. W. Cooper, also known as Ron, serves as Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 2015. He serve...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD3.46M) is above average for companies of similar size in the US market ($USD2.30M).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ALBO's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: ALBO's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Albireo Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Albireo Pharma, Inc.
  • Ticker: ALBO
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$604.055m
  • Shares outstanding: 19.26m
  • Website: https://www.albireopharma.com

Number of Employees


Location

  • Albireo Pharma, Inc.
  • 10 Post Office Square
  • Suite 1000
  • Boston
  • Massachusetts
  • 2109
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 22:02
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.